This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Friday's Health Winners & Losers

Shares of Epix Pharmaceuticals (EPIX) were among health care stocks' losers Friday, plummeting 15.6% on disappointing study results of its experimental anxiety drug.

In phase III trials, the drug, dubbed PRX-00023, did not show a significant improvement in symptoms when compared with a placebo, the study's main goal. A secondary goal was to show improvement in a certain measure of anxiety, which the company says the data trended toward but results were impacted by a higher-than-expected response in patients receiving a placebo. Shares sank 83 cents to $4.48 in recent trading.

Scolr Pharma's (DDD - Get Report) shares jumped 4.5% following an announcement that the company has entered a research collaboration with an unnamed U.S. company to develop its proposed flu drug.

The antiviral drug, administered orally, will use Scolr's CDT drug delivery technology. If successful, the companies could enter a licensing agreement to market the drug. Shares were recently trading up 11 cents, or 2%, to $5.47.

Gene Logic (GLGC) shares were up 5.2% after the company completed a review of its businesses. Based on findings from the 90-day review, the company says its so-called drug repositioning group has the capacity to significantly enhance long-term shareholder value.

Through a number of agreements with large pharmaceutical companies like Pfizer (PFE) and Roche, Gene Logic picks up drugs that have stalled in mid-stage clinical trials and returns them to development. Gene Logic shares were up 8 cents to $1.61 in recent trading.
1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
DYAX $38.41 0.00%
EPIX $2.81 0.00%
BSX $16.92 0.30%
DDD $8.07 -5.17%
AAPL $94.27 -0.76%


Chart of I:DJI
DOW 15,914.74 -99.64 -0.62%
S&P 500 1,851.86 -0.35 -0.02%
NASDAQ 4,283.5920 +14.8290 0.35%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs